The Lupus Initiative is saddened to learn of the passing of Evelyn V. Hess, MD, former ACR master member, distinguished professor emerita, founder and former chief of the division of immunology, allergy, and rheumatology at the University of Cincinnati Medical School. Over the course of her notable career, Dr. Hess made outstanding contributions to the advancement of […]
The American College of Rheumatology’s Lupus Initiative announced the award of a one-year $500,000 grant from the Office of Minority Health. Read the full press release here.
The Lupus Initiative’s® (TLI) project entitled, Teaching Fellows in Lupus, was presented at the 2015 ACR/ARHP Annual Meeting, November 6-11, 2015 in San Francisco. Teaching Fellows in Lupus aims to reduce health disparities in lupus by increasing awareness and knowledge of the disease among frontline health care providers. The project utilizes rheumatology fellows to deliver standardized lupus education […]
An abstract on The Lupus Initiative’s® (TLI) project: Practice Improvement Using Virtual Online Training (PIVOT), has been accepted for a poster presentation at the American College of Rheumatology’s annual meeting, November 6-11, 2015 in San Francisco. PIVOT, a medical evaluation simulation case study tool, was initially developed by TLI in conjunction with University of California […]
Excerpted from The Rheumatologist, August 17, 2015. The ACR’s Lupus Initiative Expands Training, Educational Resources By E. William St.Clair, MD The Lupus Initiative (TLI) has been an emergent creation inside the American College of Rheumatology (ACR) for the past six years. In 2009, the Office of Minority Health and Office of Women’s Health (now called […]
See page 6. The Lupus Initiative highlights one woman who is taking action.
Lupus Initiative panel moderator, award winning journalist Brenda Blackmon, shares her story.
Reducing Disparities in the Delivery of Healthcare to Patients with Lupus: A Q&A with Sam Lim, MD, Consortium Chair of the Lupus Initiative
President’s Perspective: New ACR Lupus Initiative Program Helps Identify and Eliminate Bias in Rheumatology Practices
ACR board president asks medical practitioners, “Are you unbiased? Are you sure?”
As the need to reduce the high burden of preventable disease and premature death experienced by racial and ethnic minorities increases, recognizing and managing bias becomes an important clinical concern, one that no provider can afford to ignore.
We all know that systemic lupus erythematosus disproportionately impacts women and racial and ethnic minorities. We also know that people of lower socioeconomic status are often diagnosed later and have poorer outcomes after diagnosis. The groups that are genetically at greater risk for SLE, namely women and minorities, are also more likely to be poor and uninsured.
Over the past three years, members of The Lupus Initiative consortium have worked together to transform lupus education by leading an effort aimed at eliminating ethnic, racial, and gender disparities in the diagnosis and treatment of lupus through education. Because of these unique collaborations, this catalytic effort not only has the potential to produce meaningful outcomes; it has also established an effective model for success in educational philanthropy.
Lupus Initiative consortium chair offers insights on the special challenges of lupus diagnosis in primary care and sheds light on how primary care physicians can ensure better outcomes for their patients with lupus.
Lupus Initiative consortium member pens an article highlighting how lupus is a touchstone for the U.S. healthcare system and care for vulnerable patients.
Former ACR board president underscores how The Lupus Initiative offers a strategic & proactive approach to patient care for the medical profession.
The Lupus Initiative salutes patients & providers that are advancing lupus care.
Excerpted from FDA News Release, dated March 9, 2011 The US Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of lupus patients with active autoantibody- positive systemic lupus erythematosus (SLE). The last drugs to receive FDA approval for the treatment of lupus were Plaquenil (hydroxychloroquine)and corticosteroids, in 1955 and aspirin in 1948. […]